360° SearchNetwork Hot Spots Trends Time Series

Formoterol

Type: Keyphrase

Name: Formoterol

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Dey, L.P. v. Sunovion Pharmaceuticals, Inc. (Fed. Cir. 2013)

Enactment of the Leahy-Smith America Invents Act in 2011 focused the patenting community on the changes of U.S. patent law from "first to invent" under the 1952 Patent Act to "first inventor to file" under the AIA as the basis for deciding priority and ... [Published JD Supra - May 24 2013]

Entities: Clinical trials, Sunovion Pharmaceuticals Inc., Invention, Patent, Formoterol

First reported May 22 2013 - Updated May 22 2013 - 1 reports

COPD patients’ CV risk increased with beta-agonists and anticholinergics

The new use of inhaled long-acting bronchodilators — beta-agonists and anticholinergics — is associated with increased cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD), with no difference in risk between the two drug ... [Published Pharmacy Magazine - May 22 2013]

Entities: Chronic Obstructive Pulmonary Disease, Anticholinergic, Patient

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Court upholds Mylan's patents on COPD drug

Federal appeals court reverses decision in case against SunovionRelated ContentPITTSBURGH — A federal appellate court has ruled in favor of Mylan in a case involving a drug for chronic obstructive pulmonary disease, the drug maker said Tuesday.Mylan said ... [Published Drug Store News - May 21 2013]

Entities: Chronic Obstructive Pulmonary Disease, Patent, Drugs, Brovana

First reported May 13 2013 - Updated May 14 2013 - 4 reports

Assessing Your Asthma is Key to Taking Control

Wendy Damonte's Health Watch ReportsMore>>More >>Jamba Juice in Carson City will host a fundraiser to support lifetime Carson City resident, Tiffani Barber who is battling stage 4 cancer.More >>Jamba Juice in Carson City will host a ... [Published KTVN - May 13 2013]

Entities: Symbicort, Corticosteroid, Asthma

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Salmeterol

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the ... [Published 7thSpace - May 08 2013]

Entities: Chronic Obstructive Pulmonary Disease, Bronchodilator, Salmeterol, Formoterol

First reported May 07 2013 - Updated May 07 2013 - 3 reports

Forest Laboratories Inc

Positive Data on Forest Combo Drug - Analyst Blog

Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate (LABA).Two fixed dose ... [Published Quote.com United States - May 07 2013]

Entities: Forest Laboratories Inc, Chronic Obstructive Pulmonary Disease, Formoterol, Phase III, Cubist Pharmaceuticals Inc

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Novel Functional Imaging of Changes in Small Airways of Patients Treated with Extrafine Beclomethasone/Formoterol

Respiration ... [Published Sexual Development - May 06 2013]

Entities: beclomethasone, Formoterol, Patient

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Forest Laboratories and Almirall Confirm Positive Results from Augment COPD Clinical TrialSUBJECTCODE04011000

Forest Laboratories, Inc. and Almirall, S.A. (ALM:MC) announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium ... [Published Individual.com - May 06 2013]

Entities: Formoterol, Almirall SA, Chronic Obstructive Pulmonary Disease, Forest Laboratories Inc

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Clinical Notes: FDA Broadens Use for JIA Drug

The arthritis drug tocilizumab was approved to treat polyarticular juvenile idiopathic arthritis in children as young as 2. Also this week: more SARS-like virus infections strike in Saudi Arabia.Actemra OK'd for Second Form of JIAThe FDA has approved ... [Published MedPage Today - May 05 2013]

Entities: FDA Food & Drug Administration, Drugs, Tocilizumab, Formoterol, Michael Taylor

First reported May 02 2013 - Updated May 03 2013 - 3 reports

Positive Phase III Results With Aclidinium/Formoterol in COPD

Positive results have been reported from the AUGMENT/COPD trial, the second 6-month pivotal phase III study of investigational fixed-dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) (Forest Laboratories/Almirall, S.A.), delivered ... [Published PT Community - May 03 2013]

Entities: Formoterol, Chronic Obstructive Pulmonary Disease, Phase III, Forest Laboratories Inc, dyspnea

First reported May 01 2013 - Updated May 02 2013 - 14 reports

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations ... [Published News-Medical.Net - May 02 2013]

Entities: Formoterol, Chronic Obstructive Pulmonary Disease, Almirall SA, Forest Laboratories Inc

First reported May 02 2013 - Updated May 02 2013 - 1 reports

GSK submits COPD drug in US and EU

Umeclidinium bromide intended as monotherapy for lung conditionGlaxoSmithKline (GSK) has submitted umeclidinium bromide for regulatory approval in the US and EU as a monotherapy for patients with chronic obstructive pulmonary disease (COPD).The drug is ... [Published PMLive - May 02 2013]

Entities: Chronic Obstructive Pulmonary Disease, GlaxoSmithKline plc, anoro, Formoterol

Quotes

...participants were provided with a "personal supply" of the formulations that they could use "however they saw fit" and that provided them with an "unfettered use of the composition for weeks at a time." The panel agreed with Dey that the use by the study participants was anything but "unfettered," citing the restrictions contained in agreements between...

Dey, L.P. v. Sunovion Pharmaceuticals, Inc. (Fed. Cir. 2013) [Published JD Supra - May 24 2013]

Chuck Bramlage, chief executive officer of Pearl Therapeutics, added "The COPD market presents a significant commercial opportunity, with estimates of annual global sales of nearly $6 Billion for the LAMA/LABA class. We believe PT003 is well-positioned to address the needs of COPD patients and become a market leader in this new and emerging class of therapies. In addition, with Pearl's unique triple-combination programme, we believe Pearl's product portfolio represents one of the industry's strongest development pipelines for treatment of COPD."

Pearl begins PT003 phase III programme to treat moderate-to-severe COPD [Published PharmaBiz - May 16 2013]

...their lives with fewer interruptions – asthma doesn't have to limit their daily activities," said Frank Trudo, MD, Medical Affairs, AstraZeneca. "National Asthma and Allergy Awareness Month is an opportune time for patients with asthma to work with their health care providers, reexamine asthma triggers and symptoms, to determine if their asthma is under control and their lungs are functioning optimally."

Assessing Your Asthma is Key to Taking Control [Published KTVN - May 13 2013]

Curtis Rosebraugh, director of the Office of Drug Evaluation II, Center for Drug Evaluation and Research at the FDA, said that "the availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD" . The drug carries a boxed warning that long-acting beta-agonists (ie fluticasone) increase the risk of asthma-related death and Breo Ellipta should not...

FDA approves GSK/Theravance COPD drug Breo Ellipta [Published Pharma Times - May 13 2013]

More Content

sort by: Date \| Relevance
Dey, L.P. v. Sunovion Pharmaceuticals, Inc. (Fe... [Published JD Supra - May 24 2013]
FOREST LABORATORIES INC - 10-K - Management's D... [Published Pharmacy Choice - May 24 2013]
Patent Watch: Dey, L.P. v. Sunovion Pharms., Inc. [Published JD Supra - May 23 2013]
COPD patients’ CV risk increased with beta-agon... [Published Pharmacy Magazine - May 22 2013]
COPD patients’ CV risk increased with beta-agon... [Published PJ Online - May 21 2013]
Court upholds Mylan's patents on COPD drug [Published Drug Store News - May 21 2013]
Mundipharma International Limited - Pharmaceuti... [Published TransWorldNews - May 18 2013]
Sunovion to Present Three Posters on Results of... [Published Yahoo! Finance - May 16 2013]
Pearl begins PT003 phase III programme to treat... [Published PharmaBiz - May 16 2013]
Pearl Therapeutics Initiates PT003 Phase 3 Prog... [Published BioSpace - May 14 2013]
Pearl Therapeutics Initiates PT003 Phase 3 Prog... [Published BizWire Express - May 13 2013]
Assessing Your Asthma is Key to Taking Control [Published KTVN - May 13 2013]
Assessing Your Asthma is Key to Taking Control ... [Published Yahoo! Finance - May 13 2013]
ASTRAZENECA PLC: Assessing Your Asthma is Key t... [Published 4 Traders - May 13 2013]
Assessing Your Asthma is Key to Taking Control [Published ADVFN India - May 13 2013]
FDA approves GSK/Theravance COPD drug Breo Ellipta [Published Pharma Times - May 13 2013]
Vectura Group plc : Vectura establishes strateg... [Published Investegate - May 13 2013]
UPDATE 3-US FDA approves Glaxo/Theravance drug ... [Published London South East - May 10 2013]
FDA approves Glaxo/Theravance drug for COPD lun... [Published Reuters India - May 10 2013]
Skyepharma PLC (SKYEF) â Interim Management Sta... [Published BioSpace - May 09 2013]
Skyepharma PLC - Interim Management Statement [Published Morningstar UK - May 09 2013]
Almirall earnings down but confident about COPD... [Published Pharma Times - May 08 2013]
Combination bronchodilator therapy in the manag... [Published 7thSpace - May 08 2013]
Positive Data on Forest Combo Drug - Analyst Blog [Published Quote.com United States - May 07 2013]
Positive Data on Forest Combo Drug Zacks [Published Yahoo! Finance - May 07 2013]
Forest Laboratories and Almirall Report Positiv... [Published Individual.com - May 07 2013]
Almirall mantiene la retribuci$n al accionista ... [Published Noodls - May 06 2013]
Novel Functional Imaging of Changes in Small Ai... [Published Sexual Development - May 06 2013]
Forest Laboratories and Almirall Confirm Positi... [Published Individual.com - May 06 2013]
Clinical Notes: FDA Broadens Use for JIA Drug [Published MedPage Today - May 05 2013]

Blogs

sort by: Date \| Relevance
3 Healthcare Stock Stories For Midweek Wellness [Published Wall St. Cheat Sheet - May 02 2013] Forest Laboratories ( NYSE:FRX ): Closing price $37.04 On Wednesday, Forest and Almirall announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial that studies the efficacy and safety of investigational ...
Forest, Almirall report positive results from A... [Published PBR - News - May 02 2013] Forest Laboratories and Almirall have reported positive results from the ACLIdinium/FORMoterol fumarate combination for Investigative use in the treatment of moderate to severe COPD (ACLIFORM/COPD) Phase III study. ...
US EQUITIES OPENING HEADLINES INCLUDING: US equ... [Published Proactiveinvestors United Kingdom website - Apr 16 2013] US equity futures point to a higher open on Wall Street, retracing some of the sharp losses seen during yesterday's session. Strong earnings from large-cap companies have also supported equity futures with Johnson & Johnson and Goldman Sachs trading ...
PERFOROMIST (Formoterol Fumarate Dihydrate) Sol... [Published DailyMed Drug Label Updates for the last seven ... - Feb 17 2013] Updated Date: Feb 11, 2013 EST ...
PERFOROMIST (Formoterol Fumarate Dihydrate) Sol... [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2013] Updated Date: Feb 11, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Almirall e Forest Laboratories annunciano risul... [Published PR Newswire: General Business - May 02 2013]
Almirall und Forest Laboratories geben positive... [Published PR Newswire: General Business - May 02 2013]
Almirall y Forest Laboratories anuncian resulta... [Published PR Newswire: Health - May 02 2013]
Forest Laboratories and Almirall Announce Posit... [Published Business Wire - May 01 2013]
Forest Laboratories and Almirall Announce Posit... [Published Business Wire Health News - May 01 2013]